Plasma cholesteryl ester transfer protein concentrations predict cardiovascular events in patients with coronary artery disease treated with pravastatin

Bristol-Myers Squibb, New York, New York, United States
Journal of Internal Medicine (Impact Factor: 6.06). 09/2006; 260(2):151-9. DOI: 10.1111/j.1365-2796.2006.01674.x
Source: PubMed


The B1B1 variant of the cholesteryl ester transfer protein (CETP) TaqIB polymorphism and high plasma CETP concentrations are associated with favourable angiographic outcomes in pravastatin-treated patients suffering from coronary artery disease (CAD). The purpose of the present study was to test whether CETP TaqIB genotypes and/or plasma CETP concentrations at baseline also predict clinical end-points in patients with CAD.
Prospective longitudinal observational study.
Primary care doctors (n=88) and hospitals (n=7) in Austria.
A total of 1620 men and women with preexisting CAD were recruited and plasma lipids were determined at study entry. 1389 hypercholesterolaemic patients were included and 1002 patients completed the follow-up.
In all patients treatment with pravastatin was started and patients were followed up for 2 years.
Cardiovascular events.
One hundred patients suffered at least one cardiovascular event. We observed significantly more events in patients within the lowest compared with the highest quartile of plasma CETP concentrations (odds ratio 3.20, CI95 1.65-6.23; P=0.001, adjusted for known risk factors of CAD). No significantly different numbers of cardiovascular events were found between CETP TaqIB genotypes.
Plasma CETP concentrations, but not CETP TaqIB genotypes, predict cardiovascular events in patients with CAD treated with pravastatin. Despite higher LDL cholesterol concentrations, high plasma CETP concentrations at baseline are associated with fewer cardiovascular events compared with low plasma CETP concentrations in CAD patients treated with pravastatin.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Use of lipid-lowering agents, mainly statins, is a proven strategy to prevent cardiovascular disease events. Because most of the beneficial effect of statins is accounted for by the improved lipid profile, more than 40 genes have been studied to ascertain whether variation therein modulates lipid response or prevention of cardiovascular disease during statin therapy. In addition, recent studies have also shown that genetic variation may stratify pleiotropic statin effects. Although this review briefly covers the pharmacogenetic implications on biochemical markers such as low-density lipoprotein cholesterol, it mainly focuses on recent findings (after 2005) on cardiovascular disease outcomes during statin therapy. Pharmacogenomic analysis of large trials of statin treatment is becoming a predominant trend. Another future direction is genome-wide analysis, which will reveal additional candidate genes to be further tested in prospective trials. The results so far are preliminary, and successful replication of the findings is needed in large unrelated populations before the evidence for any polymorphism is solid enough for clinical applications. KeywordsPharmacogenomics-Pharmacogenetics-Statins-Cardiovascular disease
    No preview · Article · Mar 2010 · Current Cardiovascular Risk Reports
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: First Page of the Article
    Full-text · Conference Paper · Jan 2005
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: We present the design of a reconfigurable VLSI architecture suitable for multirate LDPC decoding. The basic decoder fabric is a square matrix of processing elements which communicate with each other through an interconnection network. The interconnection network consists of links and switches. The connectivity between processing elements is completely defined by scheduling the interconnection network; we describe a CAD algorithm for computing efficient schedules
    Preview · Conference Paper · Jan 2005
Show more